ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) has earned an average rating of “Moderate Buy” from the sixteen research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and ten have assigned a buy recommendation to the […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) had its price objective upped by Bank of America from $26.00 to $29.00 in a report issued on Thursday morning, The Fly reports. ACAD has been the subject of a number of other research reports. Citigroup boosted their target price on ACADIA Pharmaceuticals from $21.00 to $21.60 in a […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) had its price objective boosted by JMP Securities from $23.00 to $31.00 in a report released on Wednesday, The Fly reports. They currently have a market outperform rating on the biopharmaceutical company’s stock. ACAD has been the topic of several other reports. Royal Bank of Canada restated an outperform […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) insider James Kihara sold 2,000 shares of the stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $24.15, for a total value of $48,300.00. Following the transaction, the insider now directly owns 9,144 shares of the company’s stock, […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) Director Laura Brege sold 4,500 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $24.87, for a total transaction of $111,915.00. Following the transaction, the director now owns 13,502 shares of the company’s stock, […]